BCR and leukemia: The co-existence of cytogenetically ‘normal’ cDC and moDC as well as leukemia-derived DCs (leukemic-DCs) expressing the bcr/abl fusion protein has been described in vivo in CML patients, and proportions vary among patients and DC subsets: Orsini et al. reported 50–70% of leukemic-DCs among circulating CD1c+ cDC2 [32], while Dong et al. showed that 70–95% of moDCs were leukemia-derived [33].